Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 302 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cerebellar Disorders Clear all

Conditions: Friedreich's Ataxia
Interventions: Idebenone, Placebo; Drug
Lead sponsor: Santhera Pharmaceuticals; Industry
Eligibility: 8 Years to 17 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Los Angeles, California • Philadelphia, Pennsylvania

Conditions: Friedreich Ataxia
Interventions: CTI-1601, Placebo; Biological
Lead sponsor: Larimar Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Eatontown, New Jersey

Conditions: Cerebellar Ataxia, Spinocerebellar Ataxias, Cerebellar Degeneration
Interventions: Real-time fMRI with neurofeedback of motor imagery; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Friedreich Ataxia
Interventions: Idebenone; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 9 Years to 17 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Friedreich's Ataxia, FRDA
Interventions: MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy); Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 8 Years to 16 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Spinocerebellar Ataxia (SCA), Spinocerebellar Ataxia Type 6
Interventions: Deep Brain Stimulation; Device
Lead sponsor: University of Florida; Other
Eligibility: 21 Years to 89 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin), Metastatic Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma, Small Intestine Cancer
Interventions: DNA analysis, immunologic technique, pharmacological study, iodine I 131 monoclonal antibody 3F8, 131I-3F8; Genetic · Other · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Spinocerebellar Ataxia
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 12 Years to 100 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Low-grade Cerebellar Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Medulloepithelioma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Brain Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Spinal Cord Neoplasm, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma
Interventions: veliparib, temozolomide, pharmacological study, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Friedreich Ataxia
Interventions: Idebenone; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Friedreich's Ataxia
Interventions: (+)-Epicatechin; Drug
Lead sponsor: Ralitza Gavrilova; Other
Eligibility: 10 Years to 50 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Movement Disorder
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 2 Years to 100 Years
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Anxiety Disorders, Social Phobia
Interventions: Transcranial Direct Current Stimulation; Device
Lead sponsor: Laureate Institute for Brain Research, Inc.; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Retinoblastoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: alvocidib, pharmacological study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Arcadia, California

Conditions: Friedreich Ataxia, Rare Diseases
Interventions: Geneticlly confirmed disease causing FXN mutatuion, Healthy Control; Other
Lead sponsor: Friedreich's Ataxia Research Alliance; Other
Eligibility: 4 Years to 21 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Iowa City, Iowa • Philadelphia, Pennsylvania • Memphis, Tennessee

Conditions: Ataxia Telangiectasia
Interventions: Dexamethasone sodium phosphate; Drug
Lead sponsor: Quince Therapeutics S.p.A.; Industry
Eligibility: 6 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: Los Angeles, California • Baltimore, Maryland • New Brunswick, New Jersey + 2 more

Conditions: Stroke
Interventions: Cathodal Cerebellar tDCS, Semantic Feature Analysis (SFA), Sham; Device · Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Tremor, Essential Tremor
Interventions: Deep Brain Stimulation; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 21 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Psychosis; Acute
Interventions: risperidone, aripiprazole; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 15 Years to 40 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Cowden's Disease, Cowden's Syndrome, Lhermitte-Duclos Disease, Cerebellum Dysplastic Gangliocytoma, Bannayan Zonana Syndrome, Myhre Riley Smith Syndrome, Riley Smith Syndrome, PTEN Hamartoma Tumor Syndrome, Bannayan Riley Ruvalcaba Syndrome
Interventions: Everolimus blinded oral capsules, Placebo; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 5 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Stanford, California • Boston, Massachusetts • Cleveland, Ohio

Conditions: Friedreich Ataxia, Cardiomyopathy
Interventions: Not listed
Lead sponsor: Lexeo Therapeutics; Industry
Eligibility: 6 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: La Jolla, California • Tampa, Florida • Indianapolis, Indiana + 5 more

Conditions: CACNA1A, Spinocerebellar Ataxia Type 6, Episodic Ataxia Type 2, Familial Hemiplegic Migraine-1
Interventions: N-Acetyl-L-Leucine, Placebo; Drug · Other
Lead sponsor: IntraBio Inc; Industry
Eligibility: 4 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Baltimore, Maryland • Boston, Massachusetts • Houston, Texas

Conditions: Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Visual Pathway and Hypothalamic Glioma
Interventions: cilengitide, laboratory biomarker analysis, pharmacological study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 19
States / cities: Oakland, California • San Francisco, California • Washington D.C., District of Columbia + 16 more

Conditions: Metastatic Colorectal Cancer
Interventions: Epacadostat (INCB024360) in Combination with Pembrolizumab (MK-3475) and Azacitidine (VIDAZA); Drug
Lead sponsor: James J Lee; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia

Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia

Using Real-time fMRI Neurofeedback and Motor Imagery to Enhance Motor Timing and Precision in Cerebellar Ataxia

Idebenone to Treat Friedreich's Ataxia

GABA and GSH in FRDA

Interposed Nucleus aDBS for Ataxia

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

Natural History of Spinocerebellar Ataxia Type 7 (SCA7)

ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors

Safety Study of Idebenone to Treat Friedreich's Ataxia

(+) Epicatechin to Treat Friedreich's Ataxia

Phenotype/Genotype Correlations in Movement Disorders

Cerebellar Neuromodulation to Enhance Fear Extinction and Predict Response to Exposure Therapy

Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas

Understanding the Natural History Early in the Course or Presentation of Friedreich Ataxia

Open-Label Extension of EryDex Study IEDAT-04-2022

Cerebellar Stimulation for Aphasia Rehabilitation

Deep Brain Stimulation of the Deep Cerebellar Nuclei for Refractory Tremor

Cerebellum-based Imaging Neural Markers for Antipsychotic Response

Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations

Clinical Course Of Disease In Participants With FA-CM

Pivotal Study of N-acetyl-L-leucine for CACNA1A

Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy

Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer